|
|
|
|
|
|
Kimberly initially joined Health Advances after receiving her Masters in Medical Sciences
from Harvard Medical School. Following a leave to complete her PhD research, she returned
to the firm in 2003. Kimberly received her PhD in Immunology from Harvard University for
her work exploring the contribution of CD28 to CD4+ T cell activation and the role of
intracellular signaling domains in the activation process.
Kimberly assists Health Advances’s clients in creating US and
worldwide strategies for the development and commercialization of targeted therapeutics and
companion diagnostics across multiple therapeutic areas including oncology and infectious disease.
Kimberly graduated summa cum laude from Bates College with a degree in biology and was
elected Phi Beta Kappa and Sigma Xi. While at Bates, she was recognized as a Dana Scholar
for excellence in academic and extracurricular pursuits. She completed a summer internship
in the department of Biological and Biomedical Sciences at University Hospital where she
studied the relationship between the structure and function of DAB389IL-2, now commercialized
as ONTAK® by Ligand Pharmaceuticals.
|
|
 |
|
|
|
|
